Skip to main content
Oxford University Hospitals NHS Foundation Trust

Alert Coronavirus / COVID-19

If you have a new continuous cough, a high temperature, or a loss or change to your sense of taste or smell, do not come to our hospitals. Follow the national advice on coronavirus (COVID-19).

Please find information on our services and visiting restrictions in our COVID-19 section.

Patients and visitors must wear a face covering in our hospitals.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Genetic testing for familial hypocalciuric hypercalcaemia (R152)

Background information

Familial benign hypocalciuric hypercalcaemia is an autosomal dominant disorder of extracellular calcium homeostasis, characterised by lifelong hypercalcaemia with inappropriately low urinary calcium excretion (mean urinary calcium:creatinine clearance ratio <0.01).

Identification of pathogenic variants in the genes responsible for FHH can confirm the diagnosis based on clinical / biochemical presentation. This can assist in directing patient management and whether surgical intervention is required.

It is a genetically heterogeneous condition where the types are clinically indistinguishable.

To date the following genes have been identified as causative of FHH:

CASR: Pathogenic loss of function mutations in the CASR gene account for FHH type1 (FHH1). ~65% of individuals with definite FHH are reported to have a pathogenic variant in this gene.

GNA11: pathogenic variants in this gene are causative of FHH type 2 (FHH2). Nesbit et al., 2013, NEJM, identified pathogenic GNA11 variants in >10% CASR and AP2S1 mutation negative FHH patients (although the cohort tested was small; prospective testing in clinical cohorts indicates variants in GNA11 to be a very rare cause of FHH).

AP2S1: The molecular basis of FHH type 3 (FHH3) has been identified as mutation of codon p.Arg15 of the AP2S1 gene. >20% of CASR negative FHH patients have this mutation (Nesbit et al., Jan 2013, Nature Genetics).

NHSE funded test referrals should meet the relevant NHSE eligibility criteria (pdf).

Testing strategy

Clinically affected probands:

R152.1 - analysis for small variants in the gene panel indicated below

Individual gene analysis is available to non NHSE referrals where clinically indicated

Genes tested:

Genes analysed are in accordance with the 'green high evidence of clinical association gene list in panel app: CASR, GNA11, AP2S1 (targetted codon 15 only)

Targeted analysis for known / previously reported familial variants:

  • Presymptomatic testing in clinically unaffected family members at risk of inheriting a previously reported familial pathogenic variant (R242)
  • Diagnostic confirmation in individuals at risk of inheriting a previously reported familial pathogenic variant and clinically suspected of having the familial condition (R240)
  • Segregation studies in affected family members to aid variant interpretation (R375)
  • Prenatal diagnosis is not typically requested

Target reporting times

Turnaround times for genetic / genomic testing

Sample requirements and referral information

All referrals should ideally be accompanied by a completed pre-referral form.

Clinical guidance and advice is available to referring consultants from:

Professor Rajesh Thakker, Professor of Medicine
OCDEM, Churchill Hospital

Email: rajesh.thakker@ndm.ox.ac.uk

Requesting specialties:

  • Endocrinology
  • Clinical Genetics

Specimen requirements and referring samples

Price list for non NHSE referrals (pdf)

Contact us

Oxford Genetics Laboratories - Contact us